If you’ve ever put off a treatment; RF microneedling, or filler/aesthetic injections because you were worried about the pain, you’re not alone. Comfort is one of the most common questions we hear. One newer medication getting a lot of attention in aesthetic education is Journavx (suzetrigine), a prescription pain pill that works differently from opioids.
Our team recently reviewed an education session with Dr. Lynn Nieman, a board-certified anesthesiologist on how some aesthetic practices are thinking about Journavx [6]. This post explains what Journavx is, what the research actually shows, who should be careful with it, and where the evidence stops, so you can have an informed conversation with your provider.
Key Takeaways
- Journavx (suzetrigine) is an FDA-approved, non-opioid prescription pill for moderate-to-severe acute (short-term) pain in adults, including pain after surgery [1][2].
- It blocks a pain-signaling channel called NaV1.8 on nerves outside the brain and spinal cord [1].
- In two large trials after tummy tuck and bunion surgery, it beat placebo [1][3].
- It is not approved for chronic pain. Taking it before a cosmetic procedure is an off-label use that the approval trials did not test [1][6].
- It interacts with some common medications, grapefruit, and certain birth control pills. Share your full medication list before any prescription [1].
- It doesn’t replace numbing. Topical numbing, dental blocks, and nitrous can be added if needed.
What is Journavx?
Journavx is the brand name for suzetrigine, a 50 mg oral tablet made by Vertex Pharmaceuticals. The FDA approved it on January 30, 2025, to treat moderate-to-severe acute pain in adults [2]. The FDA called it “a first-in-class non-opioid analgesic,” and it was the first drug approved in its class [2].
“Acute” is the key word. Acute pain is short-term pain from something like surgery or an injury. The label says Journavx should be used for the shortest time that fits your treatment goals, and it hasn’t been studied for longer than 14 days [1].
How does it work?
Your body sends pain signals through tiny channels on nerve cells. Journavx selectively blocks one of them, NaV1.8, found on pain-sensing nerves in the peripheral nervous system (outside the brain and spinal cord) [1]. By blocking it, Journavx reduces the pain signals that reach the spinal cord and brain [1].
This is a different pathway from opioids, which act on opioid receptors in the brain and spinal cord. Journavx is not an opioid [2].
What did the studies show?
The two main trials: tummy tuck and bunion surgery
The FDA approval rests on two randomized, double-blind trials with more than 2,000 adults [1][3]:
- Abdominoplasty (tummy tuck): 1,118 adults
- Bunionectomy (bunion surgery): 1,073 adults
Patients joined after surgery, once they already had moderate-to-severe pain. They were randomly assigned to Journavx, placebo, or hydrocodone/acetaminophen (5 mg/325 mg) for 48 hours. Everyone could use ibuprofen as a “rescue” pain reliever [1][3].
What happened:
- Journavx vs. placebo: Journavx reduced pain significantly more than placebo in both trials [1][3].
- Journavx vs. hydrocodone/acetaminophen: Neither trial showed Journavx was better than the opioid combination. After tummy tuck, results were similar. After bunion surgery, the hydrocodone/acetaminophen group scored better on average [1][3]. The researchers summarized pain relief as “similar” to hydrocodone/acetaminophen [3].
- How fast: Meaningful pain relief (a 2-point drop on a 0-10 scale) came at a median of about 2 hours after tummy tuck and 4 hours after bunion surgery, compared with 8 hours on placebo [1][3].
A broader single-arm study
A third phase 3 study gave Journavx to 256 adults with a range of surgical and non-surgical acute pain for up to 14 days. It had no placebo or comparison group. Its main goal was safety; 83% of participants rated it good, very good, or excellent for their pain [4]. Studies without a comparison group can’t show how much of that benefit came from the drug itself.
Worth knowing: The trials were funded by Vertex, the drug’s maker [3]. That’s common for approval trials, and the FDA reviewed the data independently.
Can Journavx help with aesthetic procedures?
This is where we want to be clear about what is and isn’t known.
What the label covers
Journavx is approved to treat moderate-to-severe acute pain that is already present, including pain after surgery [1]. The approval trials started the drug after surgery, once patients were in pain [1][3].
What some aesthetic practices are exploring (off-label)
Dr. Nieman described giving Journavx before painful aesthetic procedures, such as aggressive lasers or deep RF microneedling and some injectables for very anxious or very sensitive patients [6]. Taking it ahead of time to prevent procedure pain is off-label. That means it isn’t part of the FDA-approved use, and the label doesn’t set a “before procedure” timing [1]. Dr. Nieman also noted there are no clinical studies of this pre-procedure use yet [6].
Some of her points line up with good safety practice:
- It isn’t for every patient or every treatment. She said she would not use it for routine Botox or standard microneedling. She would also skip it for areas where your injector relies on your feedback (a wince can signal a needle is in the wrong layer), such as some temple or chin filler [6].
- It doesn’t replace numbing. Patients in the trials still received anesthesia, and Journavx is not a local anesthetic or a sedative [1][6].
- You may feel fine before your skin is healed. She cautioned that patients can feel so comfortable that they skip aftercare, like resting after a laser treatment [6]. Follow your aftercare instructions no matter how good you feel.
Off-label prescribing can be reasonable when a licensed prescriber judges it appropriate. It should come with a clear consent conversation about what is and isn’t proven.
What Nervana uses today
For treatments like Morpheus8 RF microneedling, your provider will walk you through comfort options at your consult (see our Morpheus8 consultation guide). We have found this to be very helpful for intra-procedural pain control.
If you’re curious whether Journavx is an option for you, bring it up at your consult. Your provider will decide based on your health history, medications, and the procedure.
Side effects
In the pooled tummy tuck and bunion trials, the side effects that happened more often with Journavx than with placebo were [1]:
- Itching (2.1% vs. 1.6% with placebo)
- Muscle spasms (1.3% vs. 0.5%)
- A rise in a muscle enzyme called CPK on blood tests (1.1% vs. 0.5%)
- Rash (1.1% vs. 0.5%)
Nausea or vomiting was common after surgery in every group, but it happened less often with Journavx than with placebo or hydrocodone/acetaminophen [1]. Few patients (0.6%) stopped Journavx because of side effects [1]. Journavx does not carry a boxed warning [1].
Most people in the trials were adult women under 65, so there’s less information on older adults [1].
Who should be careful with Journavx?
Journavx isn’t right for everyone. According to the FDA label [1]:
Medication interactions
- Strong CYP3A inhibitors: Journavx must not be taken with strong CYP3A inhibitors [1]. Examples include the antifungal itraconazole, the antibiotic clarithromycin, and some HIV medications that contain ritonavir [1][8]. This isn’t a complete list.
- Moderate CYP3A inhibitors, such as fluconazole, diltiazem, verapamil and erythromycin, need a dose adjustment by your prescriber [1][8].
- Strong or moderate CYP3A inducers should be avoided because they can make Journavx less effective [1]. Examples include rifampin, carbamazepine, phenytoin, and the supplement St. John’s wort [1][8].
- Other medications: Journavx can lower levels of some other drugs processed the same way, so your prescriber may need to check those too [1].
Grapefruit
Avoid grapefruit and grapefruit juice while taking Journavx [1].
Birth control
Journavx can make some hormonal birth control less effective. If your birth control contains a progestin other than levonorgestrel or norethindrone, the label says to use a backup non-hormonal method (like condoms) or switch methods while taking Journavx and for 28 days after your last dose [1]. Not sure what’s in your pill, patch, ring, or IUD? Ask your provider or pharmacist.
Liver, kidneys, pregnancy and breastfeeding
- Liver: Avoid with severe liver disease. People with moderate liver disease need a lower dose [1].
- Kidneys: Avoid with severe kidney failure (eGFR below 15) [1].
- Pregnancy: There’s no human data on Journavx in pregnancy [1].
- Breastfeeding: It isn’t known if Journavx passes into breast milk [1].
Tell your provider about every medication, supplement, and herbal product you take, even the ones that seem unrelated. Many interactions can be avoided with a complete list.
Is Journavx used for chronic pain?
Not on-label. Journavx is only approved for short-term (acute) pain [1]. Vertex is running phase 3 trials in painful diabetic nerve pain (diabetic peripheral neuropathy), with results expected in 2027 [5][7]. An earlier phase 2 study in sciatica-type back and leg pain (lumbosacral radiculopathy) found no difference from placebo [7]. Any chronic pain use today would be off-label and unproven.
FAQ
Is Journavx an opioid?
No. Journavx is a non-opioid that blocks the NaV1.8 pain-signal channel on nerves outside the brain and spinal cord [1][2].
Does Journavx work better than opioids?
Not in the main studies. It worked better than placebo, but it didn’t beat hydrocodone/acetaminophen in either trial [1][3].
Can I take Journavx before Botox or filler?
Journavx is approved to treat acute pain that is already present, not to prevent procedure pain. Taking it beforehand is off-label and hasn’t been studied in aesthetic procedures [1][6]. Many experts say it isn’t needed for routine Botox or standard microneedling [6]. Ask your provider whether it makes sense for your treatment.
Does Nervana prescribe Journavx?
Talk with your provider. Whether any prescription is right for you depends on your health history, your medications, and the procedure you’re planning. Your provider will make that decision at your consult.
Does Journavx affect birth control?
It can. If your birth control contains a progestin other than levonorgestrel or norethindrone, use a backup non-hormonal method while taking Journavx and for 28 days after your last dose [1].
Can I eat grapefruit while taking Journavx?
No. The label says to avoid grapefruit and grapefruit juice during treatment [1].
What are the most common side effects?
In trials: itching, muscle spasms, a rise in the CPK muscle enzyme, and rash [1].
Do I still need numbing cream?
Yes. Journavx doesn’t replace topical numbing, dental blocks, or other local anesthetics [1][6].
Ready to talk about a comfortable treatment plan?
References
- Vertex Pharmaceuticals. JOURNAVX (suzetrigine) tablets, Full Prescribing Information. Revised 1/2026. https://pi.vrtx.com/files/uspi_suzetrigine.pdf
- U.S. Food and Drug Administration. FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain. January 30, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain
- Bertoch T, D’Aunno D, McCoun J, et al. Suzetrigine, a Nonopioid NaV1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025;142(6):1085-1099. https://doi.org/10.1097/ALN.0000000000005460
- McCoun J, Winkle P, Solanki D, et al. Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain. J Pain Res. 2025;18:1569-1576. https://doi.org/10.2147/JPR.S509144
- ClinicalTrials.gov. NCT06628908: Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (phase 3). https://clinicaltrials.gov/study/NCT06628908
- Injector Bunny with Dr. Lynn Nieman. Journavx Prescribing + Lip Filler Numbing (education webinar). November 17, 2026.
- Rola AR, Bagley JR, Leppien EE, et al. Suzetrigine: A Newly FDA-Approved Non-Opioid Treatment Option for Management of Moderate to Severe Acute Pain. Innovations in Clinical Neuroscience. https://pmc.ncbi.nlm.nih.gov/articles/PMC13588656/
- U.S. Food and Drug Administration. For Healthcare Professionals: FDA’s Examples of Drugs that Interact with CYP Enzymes and Transporter Systems. https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems
This article is for education only and isn’t medical advice. Journavx is a prescription medication; only a licensed prescriber can decide whether it’s right for you. Report side effects to the FDA at https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.
